Associated Papers
A systematic review and meta-analysis of GFAP gene variants in Alexander disease.
Grossi A et al.
Scientific Reports, 2024
39420046 (PubMed )
Supplement: 41598_2024_75383_MOESM2_ESM.xlsx › Suppl._Table_2
Glial fibrillary acidic protein is pathologically modified in Alexander disease.
Lin NH et al.
The Journal of Biological Chemistry, 2024
Metabolic Enzyme Alterations and Astrocyte Dysfunction in a Murine Model of Alexander Disease With Severe Reactive Gliosis.
Heaven MR et al.
Molecular & Cellular Proteomics : Mcp, 2022
34808356 (PubMed )
Supplement: mmc7.xlsx › Sheet1
A report of two cases of bulbospinal form Alexander disease and preliminary exploration of the disease.
Song X et al.
Molecular Medicine Reports, 2021
Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity.
Battaglia RA et al.
Elife, 2019
Characterization of a panel of monoclonal antibodies recognizing specific epitopes on GFAP.
Lin NH et al.
Plos One, 2017
Functional characterization of a GFAP variant of uncertain significance in an Alexander disease case within the setting of an individualized medicine clinic.
Boczek NJ et al.
Clinical Case Reports, 2016
Composition of Rosenthal Fibers, the Protein Aggregate Hallmark of Alexander Disease.
Heaven MR et al.
Journal of Proteome Research, 2016
Astrocytic TDP-43 pathology in Alexander disease.
Walker AK et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2014
Archetypal and new families with Alexander disease and novel mutations in GFAP.
Messing A et al.
Archives of Neurology, 2012
Genetic ablation of Nrf2/antioxidant response pathway in Alexander disease mice reduces hippocampal gliosis but does not impact survival.
Hagemann TL et al.
Plos One, 2012
Select a paper to view details